Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Dr. Geoffrey Oxnard on Translating the Benefits of Molecular Oncology More Broadly: The Tissue is the Issue
Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (audio)
Dr. Sarah Goldberg on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer
Dr. Greg Riely on "I just found out I have an EGFR mutation, and I'm in the middle of chemo. What now?"
Dr. Sarah Goldberg: What Methods Do I Use to Obtain Samples for Molecular Testing?
Dr. Geoffrey Oxnard: Are Patients or Payers Objecting to Repeat Biopsy?
Dr. Sarah Goldberg on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"
Dr. Geoffrey Oxnard: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing
Dr. Rosalyn Juergens on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"
Dr. David Spigel: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Dr. Greg Riely: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (video)
Dr. Rosalyn Juergens on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer
Dr. Rosalyn Juergens on Managing Acquired Resistance to Targeted Therapies for Advanced NSCLC
What Molecular Markers Do You Prioritize for Molecular Testing in Advanced NSCLC, and Who do you Test?
Dr. Heather Wakelee on "Which molecular marker tests do you seek?"
Dr. Ravi Salgia on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Dr. Rosalyn Juergens: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
Dr. David Spigel on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer
Dr. Karen Kelly: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Dr. Ravi Salgia: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?
ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (video)
Dr. Phil Bonomi: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?
Dr. Greg Riely on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Dr. Rosalyn Juergens: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?
Living with Lung Cancer
Can or Will Specific Molecular Characteristics Help Determine Which ALK Inhibitor to Choose?
Are There Clinically Significant Differences Among the Second Generation ALK Inhibitors?
New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1
ROS-1 Rearrangements: What Are They?
Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements
Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance
Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC
ALK Rearrangements: What Are They, and Who Has Them?
TWiV #161 - Concerto in B
Discover more
Search
